Cover Image
市場調查報告書

多發性骨髓瘤:KOL (關鍵意見領袖)的考察

Multiple Myeloma: KOL Insight [2017]

出版商 FirstWord 商品編碼 531831
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
多發性骨髓瘤:KOL (關鍵意見領袖)的考察 Multiple Myeloma: KOL Insight [2017]
出版日期: 2017年07月01日 內容資訊: 英文
簡介

本報告總結了北美及歐洲的12名關鍵意見領袖 (KOL)對於多發性骨髓瘤的主要已上市藥劑及開發中藥劑的各種見解。

調查對像藥劑案例

  • 已上市藥劑
    • Dazarlex (Daratumumab:Genmab/Janssen Biotech)
    • Empliciti (Erotuzumab:AbbVie/BMS)
    • Farydak (Panobinostat:Novartis)
    • Kyprolis (Carfilzomib:(Onyx (Amgen))
    • Ninlaro (Ixazomib: 武田藥品工業)
  • 研發中藥物
    • Encorafenib (Array BioPharma)
    • Filanesib (Array Biopharma)
    • Isatuximab (Sanofi)
    • Nibormab (Opdivo:Bristol-Myers Squibb)
    • Pembrolizumab (Keytruda:Merck & Co.)
    • Plitidepsin (Aplidin:PharmaMar/中外製藥 (Roche))
    • Selinexor (Karyopharm Therapeutics)
    • Venetoclax (AbbVie/Roche)

主要討論問題

  • Amge的Kyprolis:能作為蛋白□抑制劑 (PI) 取代Velcade (武田藥品工業/J&J) 嗎?
    • KOL如何看待狀況良好的Kyprolis作為第1選擇藥的可能性?
  • Farydak (Novartis): 多發性骨髓瘤治療策略的未來性?
    • Farydak在治療演算法的定位仍不明確,KOL的見解是?
  • PharmaMar/中外製藥的Aplidin (plitidepsin):上市的可能性?
    • 已在歐洲申請販賣許可,專家對於本VEGF-R降壓調節劑的可能性的見解是?
  • KOL對於多發性骨髓瘤的抗PD-1劑的可能性的見解是?
    • Keytruda (Merck & Co)□Opdivo (Bristol-Myers Squibb) 在治療演算法的定位是否已有結論?
  • CheckMate 602:KOL的評價是?
    • 調查用於復發性難治性多發性骨髓瘤患者的Empliciti□Opdivo□Pomalyst (Celgene)□地塞米松療法
    • 缺乏PI會成為問題嗎?
  • Sanofi的Isatuximab:是否與J&J的Darzalex同樣有效?
    • Isatuximab會對上市第1號的Darzalex定位產生威脅嗎?
    • Isatuximab 在治療復發性難治性多發性骨髓瘤的角色是?
  • Array BioPharma的KIF11蛋白質抑制劑filanesib:對於多發性骨髓瘤的療效?
  • AbbVie/Roche的venetoclax:只能用在Bcl-2陽性患者嗎?能夠更廣泛地使用嗎?
    • 專家對venetoclax的評價?對混合療法的見解?
  • Karyopharm的新型exportin-1蛋白質抑制劑selinexor:KOL的見解?
目錄

Will novel therapies transform the treatment of Multiple Myeloma?

In recent years, there has been significant progress in the prognosis for newly diagnosed multiple myeloma (MM) patients. While the current range of treatment options - such as Celgene's Revlimid and Takeda's Velcade, and combination regimens of various therapies - are well established, unmet needs persist in the market for safe and effective drugs that can deliver durable treatment responses. Sanofi's isatuximab, AbbVie/Roche's venetoclax and Karyopharm Therapeutics' selinexor form part of a rich late-stage pipeline, but which candidates stand out to key opinion leaders (KOLs)? Which products and combinations are likely to succeed? Learn how KOLs see the MM market evolving in KOL Insight: Multiple Myeloma (MM). Twelve US and European KOLs provide candid insights on 5 marketed and 8 pipeline therapies targeting various aspects of the disease.

Take a tour of the report now:

  • Methodology
  • Research Objectives
  • Questions Asked
  • See the Multiple Myeloma therapies covered
  • Find out who the 6 US and 6 European KOLs are
  • Sample Pages

Top Takeaways:

  • Can Amgen's Kyprolis displace Velcade (Takeda/J&J) as the protease inhibitor (PI) of choice? Kyprolis is gaining ground, but what do KOLs think about its chances as the front-line option?
  • Is Farydak's (Novartis) future in the MM therapeutic strategy tenable? Farydak's position in the treatment algorithm remains uncertain. Can it maintain its position? KOLs provide their views.
  • Will PharmaMar/Chugai's Aplidin (plitidepsin) reach the market? A marketing authorisation application has been submitted for plitidepsin in Europe, but how do experts rate the potential of this VEGF-R down-regulator?
  • What potential do KOLs think anti-PD-1 agents have in MM? Will Keytruda (Merck & Co) and Opdivo (Bristol-Myers Squibb) find a place in the treatment algorithm?
  • How do KOLs rate CheckMate 602? Empliciti, Opdivo, Pomalyst (Celgene) and dexamethasone regimen is being investigated in rrMM patients. Could lack of a PI be problematic?
  • Will Sanofi's isatuximab be as effective as J&J's Darzalex? Darzalex enjoys first-to-market advantage but can isatuximab challenge its position? What role will isatuximab have in the rrMM setting?
  • Could Array BioPharma's filanesib, a KIF11 protein inhibitor, provide benefit in MM? KIF11protein provides a novel target, but can it become a viable option or fall by the wayside?
  • Will AbbVie/Roche's venetoclax be restricted to Bcl-2 positive patients or could it have wider application? See how experts rate venetoclax and which combinations with the drug excite them?
  • What do KOLs think about Karyopharm's selinexor, the novel exportin-1 protein inhibitor? Will selinexor replicate its early promise in the larger Phase III BOSTON study?

Quotes:

“When I consider the remedies available - or becoming available in the last one to three years - there are a lot of unmet needs; but I think we are on the way to convert Multiple myeloma from a malignant disease into a chronic disease.” EU Key Opinion Leader.

“The high-risk patients are still having a very poor survival, so although MM in general has a significant improvement in survival with all the new agents that we have, I think we are still lagging behind significantly in the number of patients with high-risk cytogenetics that lead to progression and early death.” EU Key Opinion Leader.

Sample of therapies covered:

Marketed Therapies

  • Dazarlex (daratumumab; Genmab/Janssen Biotech)
  • Empliciti (elotuzumab; AbbVie/BMS)
  • Farydak (panobinostat; Novartis)
  • Kyprolis (carfilzomib; (Onyx (Amgen))
  • Ninlaro (ixazomib; Takeda)

Pipeline Therapies

  • Encorafenib (Array BioPharma)
  • Filanesib (Array Biopharma)
  • Isatuximab (Sanofi)
  • Nivolumab (Opdivo; Bristol-Myers Squibb)
  • Pembrolizumab (Keytruda; Merck & Co.)
  • Plitidepsin (Aplidin; PharmaMar/Chugai (Roche))
  • Selinexor (Karyopharm Therapeutics)
  • Venetoclax (AbbVie/Roche)

Sample of KOLs interviewed:

KOLs from North America

  • Prof. Guido Tricot, MD, PhD. Director of Holden Cancer Centre's Bone Marrow Transplant and Myeloma Program and Clinical professor, University of Iowa, IA, USA.
  • Prof. C. Ola Landgren, MD, PhD. Hematologic Oncologist, Chief and Professor of Medicine, Memorial Sloan Kettering Cancer Centre, New York, USA.
  • Prof. Irene Ghobrial, MD. Clinical Professor of Internal Medicine, Dana Farber Cancer Institute, Boston, USA.
  • Prof. Kenneth Anderson, MD. Kraft Family Professor of Medicine, Dana-Farber Cancer Institute, Harvard Medical School and Brigham and Women's Hospital, Boston, USA.
  • Prof. Carol Ann Huff, MD. Associate Professor of Oncology and Medicine, Johns Hopkins University School of Medicine and Medical Director for the Johns Hopkins Kimmel Cancer Centre in Baltimore. USA.
  • Dr. Robert Schlossman, MD. Assistant Professor of Medicine, Dana-Farber / Harvard Cancer Institute, Harvard Medical School, Boston, USA.

KOLs from Europe

  • Dr Alberto Rocci, MD. Consultant haematologist, Manchester Royal Infirmary, Manchester, UK.
  • Dr. Charalampia Kyriakou, MD, PhD. Haematology consultant. Royal Free London NHS Foundation Trust and The North West London Hospitals NHS Trust, Northwick Park Hospital, UK.
  • Dr. Nicolas Blin, MD. Consultant, Department of Hematology. Nantes University Hospital, France.
  • Dr. Felicetto Ferrara, MD. Medical specialist in Hematology and Chief of the Hospital, Division of Hematology, Cardarelli Hospital, Napoli, Italy.
  • Anonymous German KOL, Dr. med., Head of Hematology, Research Group leader, Head of Quality Management. University Hospital Nurenberg-Erlangen, Germany.
  • Anonymous German KOL, Dr. med., Professor of medicine, Head of Oncology and Hematology department, Academic Teaching Hospital Mainz, Germany.
Back to Top